Md: Wve-003
Huntington Disease
Wave Life Sciences USA, Inc.Phase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 81/ 100
Competitive context
22 Active assets in the Huntington Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Deutetrabenazine Teva Branded Pharmaceutical Products R&D LLC | Phase 4 | BBB |
Tetrabenazine William Ondo, MD | Phase 4 | BBB |
Namenda University of British Columbia | Phase 4 | BB |
Dalzanemdor Supernus Pharmaceuticals, Inc. | Phase 3 | BB |
Cellavita-Hd Azidus Brasil | Phase 2/3 | BB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →